Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10525480 | 0.98 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4KMT2ASCD | |
| SCHEMBL13696497 | 0.96 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4KMT2ASCD | |
| SCHEMBL10035281 | 0.91 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL5344402 | 0.84 | MCHR1 (0.49) | SLC6A2SLC6A3SLC6A4CARM1PRMT1 | |
| SCHEMBL12180578 | 0.82 | KAT2B (0.56) | SLC6A2SLC6A3SLC6A4SCDEPHX2 | |
| SCHEMBL2088693 | 0.82 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4KMT2ASCD | |
| SCHEMBL1229562 | 0.82 | HRH1 (0.62) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11586746 | 0.82 | MCHR1 (0.46) | SLC6A2SLC6A3SLC6A4KMT2ACARM1 | |
| SCHEMBL2242864 | 0.82 | MCHR1 (0.51) | SLC6A2SLC6A3SLC6A4CARM1PRMT1 | |
| Hydrochloric Acid SCHEMBL3467493 | 0.81 | HRH1 (0.60) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| WO-2019149965-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITE DE STRASBOURG (FR) | 2019-08-08 | — | — | WO | disclosed |
| EP-2794611-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-9493438-B2 | 4,4-difluoro-piperidine-compounds | ROTTAPHARM S.R.L. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP | 2011-08-25 | — | — | US | disclosed |
| WO-2010056717-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | disclosed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | disclosed |
| EP-1193261-A1 | New thiadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | SSTR5, TAAR5, MC5R | SLC6A2 137/4885SLC6A3 280/4885SLC6A4 176/4885 |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | SLC6A2 151/4885SLC6A3 226/4885SLC6A4 132/4885 |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | ADRA1D, ADRA1A, ADRB1 | SLC6A2 763/4885SLC6A3 1083/4885SLC6A4 2086/4885 |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | SLC6A2 570/4885SLC6A3 198/4885SLC6A4 679/4885 |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | SLC6A2 555/4885SLC6A3 1380/4885SLC6A4 620/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SLC6A2 415/4885SLC6A3 911/4885SLC6A4 642/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | SLC6A2 555/4885SLC6A3 1380/4885SLC6A4 620/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | SLC6A2 4351/4885SLC6A3 3440/4885SLC6A4 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.